Cargando…
Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report
RATIONALE: Lung cancer is the cancer with the highest incidence and mortality in China and worldwide. Among them, 85% are non-small cell lung cancer (NSCLC). No previous reports have been published to describe the clinical effect of the immune checkpoint inhibitor (ICI) sintilimab in NSCLC yet. PATI...
Autores principales: | Zhang, Lin, Mai, Wuqian, Hao, Bo, Jiang, Wenyang, Geng, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249863/ https://www.ncbi.nlm.nih.gov/pubmed/32481252 http://dx.doi.org/10.1097/MD.0000000000019790 |
Ejemplares similares
-
Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020) -
Identification of therapeutic targets and mechanisms of tumorigenesis in non-small cell lung cancer using multiple-microarray analysis
por: Zhao, Dan, et al.
Publicado: (2020) -
Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis
por: Li, Wenjie, et al.
Publicado: (2023) -
Genomic profiling for non-small cell lung cancer: Clinical relevance in staging and prognosis
por: Bhattarai, Abhinav, et al.
Publicado: (2023) -
Intrapulmonary lymph node (stations 13 and 14) metastasis in peripheral non-small cell lung cancer
por: Bi, Lei, et al.
Publicado: (2021)